IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 133.95

Change

+0.34 (+0.25)%

Market Cap

USD 6.91B

Volume

0.46M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.10 (-0.11%)

USD 0.61B
BBH VanEck Biotech ETF

+0.65 (+0.41%)

USD 0.42B
PSCH Invesco S&P SmallCap Health Ca..

+0.19 (+0.42%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu..

+0.11 (+0.27%)

USD 0.14B
GNOM Global X Genomics & Biotechnol..

+0.05 (+0.50%)

USD 0.07B
FTXH First Trust Nasdaq Pharmaceuti..

-0.03 (-0.10%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

+0.03 (+0.24%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

+0.26 (+0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.40% 50% F 48% F
Dividend Return 0.29% 50% F 3% F
Total Return -1.11% 50% F 45% F
Trailing 12 Months  
Capital Gain -0.80% 50% F 49% F
Dividend Return 0.29% 50% F 3% F
Total Return -0.51% 50% F 46% F
Trailing 5 Years  
Capital Gain 9.28% 50% F 58% F
Dividend Return 1.45% 43% F 5% F
Total Return 10.72% 50% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 0.89% 38% F 41% F
Dividend Return 1.13% 38% F 37% F
Total Return 0.24% 50% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 21.44% 75% C 75% C
Risk Adjusted Return 5.27% 38% F 38% F
Market Capitalization 6.91B 100% F 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.